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Introduction
X-linked agammaglobulinemia (XLA) is the most common form of 
inherited agammaglobulinemia, accounting for 85% of all cases (1, 
2). In this disease, a B cell lineage developmental block, manifested 
at the transition between the pro–B and pre–B cell stages (3), leads to 
the essential lack of mature B and plasma cells, with a concomitant 
pronounced reduction of immunoglobulin levels. XLA is caused by 
defects in the gene encoding Bruton’s tyrosine kinase (BTK) (4–6). 
BTK is a cytoplasmic, nonreceptor tyrosine kinase belonging to the 
TEC family of tyrosine kinases (7) and is expressed in all stages of 
B cell development, with the exception of long-lived, antibody-pro-
ducing plasma cells (8, 9). Besides B lymphocytes, many other 
hematopoietic cells also express BTK (5, 8–10), but clinically rele-
vant functional impairment seems to be confined to this lineage. 
Thus, the severe clinical outcome of BTK mutations demonstrates 
the essential role of BTK already occurring in pre–B cell receptor 
signaling, which is a determinant for proliferation, differentiation, 
and survival of the early B cell stages (3, 11, 12).
Patients with XLA are prone to recurrent infections by pyo-
genic bacteria, such as pneumococci and streptococci. Affected 
subjects are also unduly susceptible to enteroviruses, which cause 
dermatomyositis and fatal chronic encephalomyelitis (13–16). 
The current treatment for XLA consists of prophylactic, regular 
intravenous, or subcutaneous gammaglobulin replacement ther-
apy and generous administration of antibiotics. This consider-
ably improves quality of life, but patients still suffer from chronic 
infections (17, 18). Furthermore, life expectancy is reduced despite 
appropriate care (16, 19–21).
Splicing defects have been identified as an important cause 
of genetic disease. Many mutations affecting splicing disrupt the 
regular 5′ splice site (5′ss) or 3′ss at exon-intron junctions. Further, 
mutations can create new splice sites, which may result in the inclu-
sion of intronic sequences or loss of part of the exons in the tran-
script. When such a new splice site occurs in an intron in the vicin-
ity of a suitable pseudo splice site, the intervening intronic region 
can be included in the mRNA as a cryptic exon. This mechanism 
has been observed in multiple diseases, including cystic fibrosis 
(22) and ataxia telangiectasia (23, 24) among others. In XLA, we 
have previously identified and described 2 such families (25, 26).
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exon-skipping SCOs has been used successfully to generate a 
truncated but partially functional protein (31, 32).
Here, we describe the feasibility of splice correction by pre-
venting cryptic exon inclusion as a personalized therapy for XLA. 
In order to achieve this, we designed SCOs targeting various sites 
in the pseudoexon region of BTK pre-mRNA. Different oligonucle-
otide (ON) chemistries have been developed over recent years in 
order to improve resistance to degradation, enhance target affin-
ity, and promote cellular uptake. In this study, we investigated 
SCOs with 2′-O-methyl phosphorothioate (2′OMePS) or phos-
phorodiamidate morpholino (PMO) backbone chemistries. For 
simplicity, the splice-correcting PMO-based oligomers are also 
referred to as SCOs.
The PMO was also tested in a cell-penetrating peptide–conju-
gated (CPP-conjugated) version. CPPs are a class of peptides with 
the ability to translocate rapidly into cells and to transport various 
macromolecular cargos. PMO-based SCOs conjugated with CPPs 
have been shown to be very efficient as therapeutics against splice 
abnormalities, especially in the mdx mouse model of DMD (33). 
Furthermore, we investigated nucleic acid modifications, such as 
locked nucleic acid (LNA), since they have been used successfully 
in many different settings, such as antisense gapmers, siRNAs, 
The XLA defect studied in this work arises from one of these 
families, which has an A-to-T transition in intron 4 of the BTK gene 
generating a novel 5′ss. This, together with a preexisting cryptic 
3′ss upstream in the same intron, results in the inclusion of a cryp-
tic exon (exon 4a) of 109 nucleotides between exons 4 and 5 in the 
mRNA (25). This changes the reading frame and completely abol-
ishes BTK protein expression. The erroneous inclusion of exon 4a 
prompted us to investigate the possibility of using splice-correct-
ing antisense oligonucleotides (SCOs), which bind to and restore 
the splicing of the pre-mRNA, a concept also exploited in other 
diseases, as reviewed recently (27, 28).
Apart from the splice sites themselves, splicing is also con-
trolled by short regulatory sequence motifs in both exons and 
introns. These motifs are designated exonic or intronic splic-
ing enhancers (ESEs or ISEs, respectively) or exonic or intronic 
splicing silencers (29). These are also of interest since SCOs 
targeting exonic splicing silencers have been shown to induce 
the inclusion of exon 7 in the transcript of the SMN2 gene in 
spinal muscular atrophy (30). Similarly, exonic splicing silencer 
regions have been targeted in the case of Duchenne muscular 
dystrophy (DMD), which is caused by mutations in the DMD 
gene. In this case, restoration of a disrupted reading frame by 
Figure 1. Design of SCOs using bioinformatic tools to search for ESE sites in the disease-causing pseudoexon. (A) Three different algorithms from the 
corresponding web-based servers, ESE-Finder, RESCUE-ESE, and PESX, were used, and the hits were aligned to the pseudoexon sequence to find locations 
with the highest correlation between algorithms. SCOs targeting the probable ESE regions were subsequently designed. SCOs are schematically presented 
with their binding-positions along the pseudoexon. (B) Predicted outcome of splicing, with or without SCOs, indicated schematically.
Downloaded from http://www.jci.org on February 14, 2017.   https://doi.org/10.1172/JCI76175
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
4 0 6 9jci.org   Volume 124   Number 9   September 2014
has been shown recently to have potentiating effect for antago-
mirs, it was also tested (37).
We targeted primary patient cells as well as lymphocytes from a 
genetically altered mouse created for this purpose. This transgenic 
mouse has several unique features; it carries the entire human 
mutant BTK locus and is devoid of endogenously expressed BTK 
protein. Notably, in contrast to the treatment concept for DMD, 
in which a truncated protein with reduced function is formed, the 
strategy in XLA permits the restoration of the authentic reading 
frame generating a fully functional protein. Importantly, because of 
the developmentally regulated expression of BTK, it may become 
feasible to achieve long-term correction of the disease phenotype. 
Moreover, besides proving the viability of splice-modifying therapy 
for a novel target disease both ex vivo and in vivo, we demonstrate 
for the first time that both primary B cells and primary monocytes 
are amenable to splice correction strategies.
Results
Design of SCOs using bioinformatics tools. Different SCOs directed 
against the BTK pseudoexon region were designed, taking into 
consideration not only the 3′ss and 5′ss of exon 4a, but also puta-
tive ESE sites. For this purpose, we used 3 different algorithms 
from the web-based servers ESE Finder, PESX, and RESCUE-ESE. 
The sequence hits were aligned to exon 4a, as depicted in Figure 1, 
which also shows the studied mutation and the expected out-
comes with or without splice correction. This analysis prompted 
us to generate a set of SCOs, as schematically indicated in Figure 1. 
They were designed to cover the 3′ss and 5′ss and the ESEs sites 
that demonstrated the most concordance between the algorithms 
used. The first set of SCOs was composed of the commonly used 
2′OMePS modification, taking into consideration the GC con-
tent, self-dimerization, and nucleic acid melting temperature 
(Tm) values (38). Additional sets were then designed with vari-
ous modifications and lengths. A schematic representation of the 
SCOs is shown in more detail in Supplemental Figure 1 (supple-
mental material available online with this article; doi:10.1172/
JCI76175DS1), and the modifications are indicated in Table 1.
SCOs restore luciferase mRNA in a reporter cell line model. We first 
designed a reporter construct containing the expression cassette 
for a fusion of EGFP and firefly luciferase but interrupted by the 
mutated patient-derived BTK intron 4. When uncorrected, this mini-
gene produces a corrupt EGFP-luciferase mRNA. However, intro-
duction of an SCO capable of rescuing the splicing of the mutated 
intron would promote restoration of EGFP-luciferase fusion protein 
expression. The model was constructed as a first functional read-
out for SCO activity and used to generate a stable U2OS reporter 
cell line expressing the above-mentioned corrupt transcript. Sub-
sequently, the fully 2′OMePS-modified SCOs (sequences depicted 
in Table 1) were transfected, and luciferase enzymatic activity was 
determined (Figure 2A). Several of the tested SCOs showed prom-
ising results when compared with the unrelated, control SCO 705 
directed against a mutated β-globin intron (39). SCO 187, covering 
the 5′ss, performed the best in these experiments, whereas SCO 
165, covering the 3′ss, demonstrated very low efficacy. SCOs 186, 
187, and 190 were chosen for further experiments. SCOs 186 and 
190 were selected because of their activity and the fact that they 
were not targeted to splice sites but instead to the predicted ESEs.
anti-microRNAs (antagomirs), and anti-gene approaches (34, 35). 
An LNA-containing ON with its 3′-endo conformation is consid-
ered to be an RNA mimic, making it effective toward structured 
RNA regions, which can be beneficial when targeting pre-mRNAs. 
This is due to the fact that position-dependent substitution with 
LNA bases changes the thermodynamic property of the duplexes 
(34, 36). Additionally, we also investigated LNA in combination 
with other derivatives, such as unlocked nucleic acid (UNA) or 
amino-glycyl-LNA (34). Moreover, since the nonbase modifier 
N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine (ZEN) 
Table 1. SCOs used in the study
ON (SCO) Sequence (5′→3′)
2′-O-methyl RNA –
164.18 ugagacuuaccaccuccu
165.18 uugcucuccuaaacagau
186.18 cagaguucucaggaugua
187.18 gagacuuaccacuuccuu
188.18 cugagacuuaggacuucc
190.18 auuuguaguucuugcucu
191.18 caaacugaagaccaaauu
217.18 agacuuaccacuuccuuu
218.18 ccugagacuuaccacuuc
705.18 (unrelated control) ccucuuaccucaguuaca
LNA/2′-O-methyl RNA and DNA –
190.15-5LNA uTugTagTucTugCu
187.15-5LNA aGacTuaCcaCuuCc
187.18-6LNA gAgaCuuAccAcuTccT
187.12-8LNA AcTTaCCaCTTc
187.12-8LNA-4LNAgly AcXXaCCaCXXc
187.10-9LNA TTACCaCTTC
186.15-3LNA gAguucuCaggauGu
186-15-5LNA gAguTcuCagGauGu
186.15-6LNA-2UNA gAgTucuCaGgaTGu
186.15-3LNA-2UNA gAguucuCaggauGu
186.12-8LNA-3LNAgly TXcXCAggAXgT
186.12-8LNA-4LNAgly TXcXCAggAXgX
186.12-8LNA-5LNAgly XXcXCAggAXgX
186.12-8LNA TTcTCAggATgT
5′186.12-7LNA AgTTcTCagGaT
GAA.12-6LNA cTaTaTTCaCga
GAA.19-3LNA cuTccuuuTcuggcuuTca
GAA.19-6LNA cuTccTuuTcuGgcTuuCa
Scrambled cAcuCuaTauAacTg
ZEN LNA/2′-O-methyl RNA –
186.15-5LNA-ZEN g/ZEN/AguTcuCagGauG/ZEN/u
186.18-ZEN c/ZEN/agaguucucaggaugu/ZEN/a
PMO & B-PMO –
B-PMO 186.25 B-peptide-CTACAGAGTTCTCAGGATGTAAGCA
Scrambled B-PMO (DMD) B-peptide-GGCCAAACCTCGGCTTACCTGAAATT
B-peptide N-RXRRBRRXRRBRXB-C
B-peptide was conjugated to PMO 186.25 to generate B-PMO 186.25. 
2′-O-methyl RNA SCOs (including those modified by LNA and ZEN) 
have phosphorothioate backbone. LNA bases are in uppercase letters; 
2′-O-methyl RNA bases are in lowercase letters; UNA bases are underlined; 
DNA bases are in bold letters; “X” represents amino-glycyl-LNA-T.
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of the corrected form at low SCO concentrations. The 190 series 
of SCOs was not further assessed, since at higher concentrations 
there were signs of toxicity in the form of cell death 24 hours after 
transfection (data not shown).
Based on these results we further modified the 186 and 187 
series, including a reduction of the ON length further to 10 to 12 
nucleotides. We also synthesized 3 additional SCOs, referred to as 
the GAA series. These were designed to target GAA-triplets, known 
to be present in certain splicing-enhancers (26, 50), as shown in 
Supplemental Figure 1 and Table 1. Supplemental Figure 2 depicts 
the effect of SCOs derived from the 186, 187, and GAA series, as 
analyzed by RT-PCR. The doses were lowered, as compared with 
previous experiments (Figure 2), in order to identify the most 
potent SCOs. As can be seen in Supplemental Figure 2, LNA-mod-
ified SCOs displayed higher potency as compared with their corre-
sponding 2′OMePS versions. 186.15-5LNA and 186.15-3LNA (with 
5 and 3 LNA substitutions, respectively) showed the best efficiency 
SCO chemistry affects splice correction activity in reporter cell 
line. We modified the selected SCOs with LNA bases, which are 
known to significantly enhance Tm and increase the efficiency of 
ONs both in vitro and in vivo (40–44). More specifically, we chose 
a 2′OMe RNA backbone with LNA modifications, as this combi-
nation has previously demonstrated high potency (45–48). Since 
size-reduced SCOs are generally considered to be more efficient 
(34, 42, 49), with lowered risk of off-target effects and improved 
uptake, we designed LNA-modified 15-mer versions of the 186, 
187, and 190 series (Supplemental Figure 1 and Table 1). Figure 2  
shows the activity of LNA-modified SCOs in the U2OS reporter 
cell line, as measured by luciferase expression and as also con-
firmed by the correction of mRNA determined by RT-PCR. It is 
clearly shown that the LNA-modified SCOs mediate enhanced 
luciferase activity at low concentrations. The same tendency 
was confirmed at the RNA level, at which we observed a reduc-
tion of the aberrant mRNA band and a concomitant appearance 
Figure 2. Splice correction–induced upregulation of reporter minigene activity. The U2OS cell line stably carrying a minigene interrupted by the 
mutated BTK intron 4 was transfected with different SCOs, and efficacy was measured as luciferase activity or mRNA restoration. (A) The relative 
luciferase activity in comparison to nontreated cells (mock) 24 hours after SCO transfection. “705” indicates an unrelated control SCO, targeting position 
705 of a mutated β-globin intron, not complementary to the BTK pre-mRNA. All tested SCOs are 2′OMePS based (Table 1). Data represent mean + SD of 
3 independent experiments, each with 2 replicates. **P ≤ 0. 01, ***P ≤ 0.001, versus 705. (B) Increase in luciferase activity by 2′OMePS-modified SCOs 
versus LNA SCOs is presented as fold increase over nontreated cells (mock). Graph represents mean + SD of 3 independent experiments, each with 2 rep-
licates. **P ≤ 0. 01, ****P ≤ 0.0001, 186.18 versus 186.15-5LNA. (C) Total RNA RT-PCR showing the 389-bp and 271-bp bands corresponding to aberrant 
and corrected (with BTK intron 4 excised) mRNA bands, respectively, with a lower band of ribosomal RNA (18S) serving as an RNA quality control. The 
lane on the right represents RNA input from nontreated (NT) cells. “Scr” represents the control LNA/2′OMePS SCO not complementary to the reporter 
gene sequence (Table 1). A representative gel from 2 independent experiments is shown. Statistical significance was determined using 1-way ANOVA, 
followed by Bonferroni’s multiple-comparison test.
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that ZEN modification is more useful when used in the context of 
a pure 2′OMe backbone and not when combined with shorter LNA 
ONs. Taken together, these additional modifications did not show 
enhanced activity and were not studied further.
LNA-based SCOs and PMOs conjugated to a CPP are efficiently 
taken up (gymnosis) in the reporter cell line. We next investigated 
the naked uptake efficiency in the reporter cell line under “gym-
nosis” conditions. The term gymnosis was coined by Stein et al. 
to describe uptake of LNA gapmers by cells in the absence of any 
transfection reagent (53). The authors suggested that this mode 
of in vitro delivery better correlated to in vivo uptake, making 
this method of general interest. Compared with lipofection, con-
siderably higher concentrations of ONs are needed for gymnosis. 
in the reporter cell assay. The 12-mer versions of both the 186 and 
187 series did not exhibit any enhanced activity under these in vitro 
conditions, and the 10-mer of SCO 187 was inactive (Supplemen-
tal Figures 2 and 3). Moreover, the newly designed GAA series did 
not show better efficiency compared with 186.15-5LNA or 186.15-
3LNA and was therefore not studied further.
In addition, we investigated 3 more chemical modifications 
(Table 1): amino-glycyl-LNA, UNA, and the nonbase modifier 
ZEN. The amino-glycyl modification adds a glycyl residue to the 
N2′ position of 2′-amino-LNA, thereby providing a positive charge 
(51). UNA is known to decrease the Tm and destabilize the duplex, 
which potentially could increase target specificity if appropriately 
designed (52). ZEN is a naphthyl-azo modifier; when placed at 
or near both ends of a 2′OMe ON, it 
increases Tm and enhances the sta-
bility against endo- and exonucleases 
(37). These new modifications were 
also tested in the reporter cell line 
model. As can be seen in Supple-
mental Figure 3, the glycyl-modified 
12-mer versions of 186 and 187 series 
showed reduced activity with increas-
ing numbers of amino-glycyls cor-
relating to further reduction in activ-
ity. This was somewhat unexpected, 
since the reduced net negative charge 
potentially could have enhanced their 
splice-correcting capacity by allow-
ing better hybridization to the cog-
nate pre-mRNA. On the other hand, 
decreased net negative charge might 
also have reduced the complexation 
with the transfection reagent Lipofect-
amine 2000, which potentially could 
have altered both the complex con-
formation and the amount transfected 
into cells. Conversely, UNA incorpora-
tion into the 186 series of SCOs caused 
reduced activity at low LNA content, 
whereas with higher LNA content 
the activity was somewhat restored. 
Moreover, ZEN-modified SCO 
(186.15-5LNA-Zen), as compared with 
186.15-5LNA (Supplemental Figure 2), 
did not show much difference in activ-
ity. The slightly longer 186.18-ZEN had 
almost the same effect as 186.15-5LNA 
and 186.15-3LNA. This might suggest 
Figure 3. Splice correction–induced upregulation of reporter minigene 
activity following naked uptake of SCOs. SCOs from the 186 series, 
including PMO 186.25, with and without the CPP moiety (B-PMO 186.25), 
were tested, and activity was measured as restoration of mRNA. A concen-
tration of 6 μM was used for the scrambled control SCO (Scr) (Table 1). A 
representative gel from 2 independent experiments is shown.
Figure 4. Full-length human mutated BTK pre-mRNA corrected by SCOs yielding normal-sized transcripts 
and detectable BTK protein. (A) B cells from human BAC transgenic mice were treated with 1.6 μM or  
3.2 μM 186.15-3LNA SCO and analyzed by RT-PCR. To identify human RNA in cells from BAC transgenic and 
KO mice, a primer pair only detecting human BTK was used. To measure endogenous mouse Btk mRNA 
levels in splenocytes derived from WT mice, a different primer set selective for mouse Btk was used. A rep-
resentative gel from 3 independent experiments is shown. Ribosomal RNA (18S) was used as an RNA qual-
ity control. (B) FACS analysis of cells 48 hours after treatment with 186.15-3LNA. B cells were stained with 
antibodies directed against CD19 or BTK protein (recognizing both mouse and human protein). Histograms 
for BTK expression in each sample from a representative experiment as well as the percentage of corrected 
cells from 3 independent experiments are shown (mean + SD). A concentration of 3.2 μM was used for the 
scrambled control SCO (Table 1). Mean fluorescence intensity, WT NT: 2,314; BAC SCO treated: 1,210. Per-
centage of WT BTK RNA was calculated as WT RNA fraction × 100/(misspliced + WT RNA fractions).
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We selected the most efficient SCOs based on the results from 
the lipofection experiments and assessed their gymnotic activ-
ity. Although 186.15-5LNA exhibited good activity, we continued 
with the similarly efficient 186.15-3LNA, owing to the fact that 
reduced LNA content potentially could reduce off-target effects 
(45). Although ZEN-modified SCOs had similar activity compared 
with the LNA-containing 186.15 versions, they could not be stud-
ied, since their availability was limited.
In addition, we also investigated the PMO backbone (54, 55), 
with the 186 sequence in the gymnosis setting. Owing to the rules 
of PMO design, this SCO was further extended to be 25 nucleo-
tides (Supplemental Figure 1 and Table 1). The rationale for length-
ening PMOs is the lower target affinity (56). We further conjugated 
the PMO with a CPP moiety named B-peptide (B-PMO), since it is 
known to be very active for exon skipping in the mdx mouse model 
(57). Thus, the PMOs tested were either unmodified or covalently 
conjugated to B-peptide.
As can be seen from Figure 3, in gymnosis setting, 186.15-
3LNA and B-peptide–conjugated PMO 186.25 (B-PMO) showed 
high potency in the reporter cells when analyzed by RT-PCR. 
We also tested higher (up to 10 μM) concentrations of PMO 
186.25, which were devoid of any CPP; however, the exon-skip-
ping effect was very low.
Generation of a transgenic mouse carrying the mutated human 
BTK locus. In order to have access to an unlimited supply of mutated 
B-lineage cells as well as a relevant in vivo model, we generated a 
mouse carrying the corresponding human BTK locus. A suitable 
BAC clone named RP11-125I5 was chosen for the development 
of BAC transgenic mice. This clone encompasses 175 kb and con-
tains an extended human genomic BTK locus. The BAC was sub-
sequently subjected to site-specific mutagenesis, generating a sin-
gle-point mutation at position 602 of BTK intron 4, the very same 
A-to-T change as seen in the XLA-family described previously. We 
confirmed that the BAC transgenic mice carry the mutated human 
BTK gene by sequencing of chromosomal DNA (data not shown). 
The founder animals were then backcrossed onto Btk knockout 
(KO) mice in order to generate transgenic animals with a disrupted, 
nonfunctional endogenous Btk locus, which were therefore only 
capable of expressing the mutated human BTK gene (Supplemen-
tal Figure 4). Throughout this report we refer to these mice as BAC 
transgenic mice. We also verified that the insertion of the transgene 
did not influence hematopoietic development; Supplemental Fig-
ure 5 shows that the common lymphoid progenitors and B cell com-
partment are similar in Btk KO and BAC transgenic mice.
SCOs correct mRNA and restore BTK protein in primary B cells ex 
vivo. To test the activity of the SCOs in the context of a full-length 
pre-mRNA transcribed from the mutant human BTK gene, we 
isolated splenic B cells from mice expressing the human mutant 
BTK transcript. As control, we used B cells from WT and Btk KO 
mice. For transfections of SCOs, we optimized a protocol for 
electroporation of mouse primary B cells. At 48 hours after elec-
troporation, cells were collected, and human BTK RNA was ana-
lyzed by semiquantitative RT-PCR, using primers detecting only 
human BTK. Another primer set was used to specifically amplify 
mouse Btk RNA in order to verify that this transcript is unaffected 
by the SCOs (Figure 4A). The results clearly show that, by using 
SCO 186.15-3LNA, splicing of the full-length human mutant BTK 
pre-mRNA was corrected, as demonstrated by the appearance of 
a lower molecular weight amplicon corresponding to the size of 
unmutated, native BTK mRNA. The correction was also verified by 
sequencing the cDNA (data not shown).
The RT-PCR results were also confirmed by flow cytometry 
analysis on cells collected 48 hours after transfection (Figure 4B). 
As can be seen from Figure 4B, treatment with 186.15-3LNA gen-
Figure 5. Enhanced survival and anti-IgM–induced BTK tyrosine phos-
phorylation in SCO-treated BAC transgenic B cells. (A) Spleen B cells 
from BAC transgenic mice were treated with 3.2 μM SCO (186.15-3LNA or 
scrambled control) and stimulated with 20 μg/ml anti-IgM 48 hours after 
electroporation (time 0). Cells were counted, and viability was determined 
by trypan blue exclusion 24 and 48 hours after stimulation. The initial 
number of cells from both WT and BAC transgenic mice was 2 × 106. 
Data represent 2 independent experiments with duplicates. Note that 
nontreated and scrambled ON–treated cell numbers overlap. Statistical 
significance was analyzed by using 1-way ANOVA followed by Bonferroni’s 
multiple-comparison test. ****P ≤ 0.0001 for BAC SCO treated versus BAC 
Scr and NT at 24 hours. (B) Analysis of BTK tyrosine phosphorylation after 
3.2 μM SCO (186.15-3LNA) treatment and anti-IgM stimulation (20 μg/ml). 
Blots show pY551 phosphorylation of BTK and total BTK. Whole cell 
lysate (WCL) analysis shows BTK protein and actin. Each duplicate (–/+) 
corresponds to starved or anti-IgM–activated conditions. A representa-
tive blot is shown from 2 independent experiments. Note that the higher 
molecular weight band, located immediately above the pY551-BTK band 
in activated samples (IP pY551 gel), is of unknown origin and unrelated 
to BTK, since it also exists in B cells obtained from Btk KO mice follow-
ing stimulation. The bar graph shows the quantitative analysis of Y551 
phosphorylation as a percentage of relative intensity signal from the blots 
according to ImageJ Software.
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erated a mean of over 40% of cells expressing substantial levels 
of BTK protein. These experiments demonstrate that not only 
the reporter minigene-derived transcript carrying the mutated 
BTK intron, but also the full-length human BTK pre-mRNA is 
amenable to SCO therapy.
SCOs restore functional BTK in primary B cells from the BAC 
transgenic mouse. Since we could conclusively show the presence of 
BTK protein by flow cytometry analysis, we investigated whether 
the synthesized protein is also functionally active. For this pur-
pose, 2 functional assays were carried out, cell viability and phos-
phorylation of the BTK regulatory loop tyrosine (Y551).
The rationale for the cell viability test is that impaired matura-
tion and survival of B cells are hallmarks of XLA (1, 2, 13). Moreover, 
it is known that BTK-deficient mouse B cells do not proliferate in 
response to anti-IgM stimulation, while WT cells 
do (58, 59). Therefore, we stimulated BAC trans-
genic mouse B cells 48 hours after SCO treatment 
with anti-IgM and incubated them for another 
24 or 48 hours in the absence of the survival-pro-
moting CpG stimulus (see Methods), conditions 
rather harsh for primary B cells. Figure 5A shows 
the viability of primary B cells after 24 or 48 hours 
of incubation with anti-IgM. As seen, under these 
experimental conditions SCO-treated BAC trans-
genic B cells showed enhanced survival compared 
with nontreated or scrambled, SCO-treated cells. 
As a sign of the harsh environment, WT mouse B 
cells were also reduced in numbers. As a second 
proof of BTK functionality, we analyzed the BTK 
phosphorylation after B cell receptor stimulation. 
In normal B cells, upon anti-IgM treatment, B cell 
receptor–induced signaling leads to tyrosine Y551 phosphorylation 
of BTK. The corresponding tyrosine is conserved in all cytoplasmic 
protein-tyrosine kinases and upon phosphorylation significantly 
enhances their catalytic activity owing to a conformational change 
(3, 13). SCO-treated B cells from BAC transgenic mice were com-
pared with B cells from WT mice. 48 hours after electroporation, 
cells were serum starved for 6 hours and subsequently incubated 
with 20 μg/ml anti-IgM before harvest. BAC transgenic B cells 
treated with 186.15-3LNA SCO showed pronounced phosphoryla-
tion when activated with anti-IgM (Figure 5B). The level was almost 
as high as in WT cells, suggesting functional restoration of BTK.
B-PMOs efficiently promote splice correction in primary B cells. 
We next evaluated the effects of naked delivery into primary cells. 
The non-PMO SCOs, initially evaluated in the reporter gene assay 
(Supplemental Figure 2), were again selected based on potency 
and assessed in primary B cells. In contrast to the gymnotic effect 
seen in the reporter cell line, we were unable to detect any signifi-
cant reproducible correction of the BTK mRNA in primary B cells 
under these conditions (data not shown). We subsequently evalu-
ated the B-PMO 186.25 as well as the corresponding control, PMO 
186.25. Notably, treatment with 3 μM B-PMO 186.25 produced 
corrected BTK mRNA (Figure 6A) as well as restored BTK protein 
expression (Figure 6B) in B cells from the BAC transgenic mice.
Figure 6. B-PMO–mediated restoration of BTK mRNA and protein in pri-
mary spleen B cells from human BAC transgenic mice. Cells were treated 
with PMO 186.25 or B-PMO 186.25 in different concentrations. “Scr” 
indicates a B-PMO SCO for an unrelated target (DMD). (A) RT-PCR prod-
ucts from SCO-treated B cells at 1 and 3 μM concentrations. Ribosomal 
RNA (18S) serves as an RNA quality control. Of note, for the splenocytes 
derived from WT mice, a different primer set selective for mouse Btk 
was used. The percentage of WT BTK RNA was calculated as WT RNA 
fraction × 100/(misspliced + WT RNA fraction). (B) Western blot from the 
same treatment. Experiments were repeated 3 times, and representative 
gels are depicted. Of note, for this experiment, anti-BTK from BD (see 
Methods) was used, yielding different unspecific bands. The bottom band 
originates from BTK, while the top band is unspecific. The lanes separated 
by a black line were run on the same gel, but since some lanes were 
considered uninformative, they were omitted as indicated by the black 
line. The bar graph shows the quantitative analysis of BTK protein as a 
percentage of relative intensity signal according to ImageJ Software. Scr, 
treated with scrambled ON.
Figure 7. Restoration of BTK protein expression after splice correction in pro–B cells from BAC 
transgenic mice. Cells were electroporated with the 186.15-3LNA SCO. After 48 hours, cells were 
stained with anti-CD19 and anti-BTK (recognizing both mouse and human protein) for FACS 
analysis. Numbers in the 3 right upper quadrants indicate the percentage of CD19-positive and 
BTK-positive cells. The experiment was repeated twice with a similar outcome, and a represen-
tative result is presented.
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IL-7, the expansion of pro–B cells was induced in vitro 
(see Methods). After 9 days, an essentially pure pro–B 
cell population was obtained (Supplemental Figure 
6). We subsequently transfected these cells with the 
186.15-3LNA SCOs and assessed BTK protein expres-
sion at 48 hours. Encouragingly, as many as 33.8% of 
the pro–B cells were BTK positive (Figure 7).
In vivo administration of SCOs restores BTK expres-
sion in BAC transgenic mice. In order to investigate 
whether the SCOs also had the capacity to correct the 
defect in vivo, 4 animals were treated with a multiple-
dose regimen using B-PMO 186.25. They received 
B-PMO 186.25 (30 mg/kg) 4 times: 3 doses intrave-
nously every second day during 1 week, followed by a 
single subcutaneous dose; animals were assayed after 
another 3 or 4 days, respectively. As is depicted in 
Figure 8, A and B, and Supplemental Figure 7, a robust 
therapeutic effect was observed both in the bone mar-
row and in the spleen. In contrast to control mice, all 
treated mice expressed corrected BTK mRNA as well 
as BTK protein. Moreover, we isolated B cells from 2 
treated and 2 untreated animals in order to be able to 
analyze BTK restoration specifically in this cell type. 
As shown in Figure 8C, we found that B-PMO was 
taken up by B cells both in bone marrow and spleen, as 
evidenced by the restored BTK expression.
Collectively, this suggests that the splice correction 
concept could become a viable treatment option for 
patients with XLA, although standardization of multi-
ple parameters is needed prior to any clinical approach.
SCOs correct splicing and restore BTK protein in 
monocytes from patients with XLA ex vivo. As a final 
proof of concept in a human setting, we applied our 
strategy to primary patient cells. Similar to B cells, 
monocytes express the BTK gene but, in contrast, do 
not need BTK protein for normal development or sur-
vival (9, 13). Since patients with XLA essentially lack 
circulating B cells but do have normal numbers of cir-
culating monocytes, we obtained monocytes from a 
patient with the BTK intron 4 cryptic splice site muta-
tion. Since splicing factors in mice and humans are 
similar but not identical, it was important to ascertain 
that splice correction of full-length pre-mRNA also 
could take place in primary patient cells.
Electroporation conditions for transfection of 
SCOs into human monocytes were optimized, and 
their therapeutic effect was assessed. Using 186.15-
3LNA, splice correction was observed for BTK both 
at the RNA (Figure 9A) and protein level (Figure 9B). 
Moreover, we also evaluated naked uptake of B-PMO 186.25 in 
patient monocytes, and SCOs readily restored BTK mRNA in these 
cells (Figure 9C) as well as yielded the corresponding protein dose 
dependently (Figure 9D). Even at a very high concentration (10 μM), 
PMO 186.25, devoid of the CPP moiety, did not restore BTK pro-
tein synthesis, suggesting the crucial importance of the CPP.
Thus, the results obtained in splice-corrected monocytes 
derived from a patient with XLA are in concordance with the 
SCOs restore BTK protein expression in pro–B cells from the BAC 
transgenic mouse. Patients with XLA are devoid of mature B cells but 
harbor differentiation-arrested pro–B cells in their bone marrow 
(13, 60). Because of this fact, it was important to establish whether 
these cells are also amenable to SCO treatment as a proof of con-
cept. For this reason, we first isolated and differentiated c-KIT+ pro-
genitor cells from the bone marrow of BAC transgenic mice. With 
support of OP9 stromal cells, Flk-2/Flt3 ligand, KIT ligand, and 
Figure 8. Restoration of BTK expression upon splice correction after in vivo treatment 
of BAC transgenic mice. Four mice were treated with B-PMOs, as described in Methods, 
and assayed for BTK restoration. (A) RT-PCR analysis of total spleen and total bone 
marrow cells from B-PMO–treated transgenic mice. A representative gel from 2 animals, 
both from the treated and the untreated group, is shown. “WT-2” represents RNA from 
normal mice, and the slightly smaller amplicon in this lane results from a differential 
primer set discriminating human and mouse RNA. To ascertain the detection of corrected 
transcripts for samples from treated and untreated BAC transgenic animals, we decided 
to use 3 times more cDNA and 5 more amplification cycles. (B) Western blot analysis of 
BTK restoration in 2 of 4 treated animals; total cells from bone marrow and spleen. (C) 
Western blot analysis of the isolated B cells both from spleens and bone marrow, show-
ing BTK expression from 2 representative animals. The percentage of WT BTK RNA was 
calculated as WT RNA fraction × 100/(misspliced + WT RNA fraction). Bar graphs show 
the quantitative analysis of BTK protein as a percentage of relative intensity according to 
ImageJ Software. T, treated.
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Mutations interfering with splicing events are estimated 
to account for a substantial amount of all alterations leading 
to disease (62), and XLA is no exception, with 14% of all muta-
tions being caused by defects related to splicing (63, 64). In this 
study, we investigated a case of XLA caused by a single nucleotide 
replacement (A to T) in intron 4 of the BTK gene, which leads to 
aberrant splicing resulting in the inclusion of a cryptic exon con-
taining an in-frame termination codon. The aim was to promote 
the exclusion of the erroneous exon and restore normal splicing 
in both patient with XLA and mouse model cells. Here, we have 
tested a number of ON chemistries and demonstrated their differ-
ent properties and utility as therapeutics in leukocytes.
Design of efficient SCOs requires careful examination of both 
the Tm and the uniqueness of the target sequence and, when pos-
sible, analysis of the secondary structure of the target site. Fur-
thermore, the in vivo activity of any SCO is not only dependent on 
hybridization properties, but also on resistance to degradation and 
clearance as well as on uptake and intracellular release in the target 
cell. We initially tested a battery of 2′OMePS RNA ONs in a model 
cell line expressing an EGFP-luciferase fusion reporter gene inter-
rupted by the BTK intron 4 with the same mutation as in the studied 
family with XLA. We scanned the whole exon 4a by designing differ-
findings in B lymphocytes from BAC transgenic mice both in 
vitro and in vivo. Collectively this demonstrates that splicing of 
full-length mutant human BTK pre-mRNA can be efficiently cor-
rected by the SCOs, thereby suggesting that our strategy is viable 
in a human setting.
Discussion
In this report, we describe a novel BAC transgenic mouse model 
for human XLA and demonstrate its feasibility for the study of 
splice correction therapy. To the best of our knowledge, there is 
only a single existing human transgenic animal model for hemato-
poietic disease caused by aberrant splicing (61). The unique fea-
tures of our transgenic mouse are that the entire affected locus 
is of human origin and that the corresponding endogenous gene 
has been deleted. This is also the first human transgene model for 
treatment strategies caused by defective splicing in the lymphoid 
compartment. Furthermore, owing to the fact that the BAC also 
encompasses the HNRNPH2 splice-factor encoding gene, these 
mice express an additional component of human origin, mak-
ing this model even more similar to the situation in XLA. Taken 
together, this suggests that our human BAC transgenic mouse 
could become of broad interest.
Figure 9. SCO-induced BTK restoration in patient monocytes. (A) Results from RT-PCR 48 hours after electroporation of monocytes from a patient with 
XLA with the intron 4 mutation. Monocytes were transfected with 1 μM 186.15-3LNA. Human control monocytes were also included. Ribosomal RNA (18S) 
serves as an RNA quality control. (B) Western blot showing BTK protein 48 hours after electroporation with or without treatment with 1 μM 186.15-3LNA. 
The right lane with a mouse B cell sample serves as a positive control for BTK (mouse and human BTK protein are both composed of 659 amino acids and 
recognized by the same antiserum). (C) RT-PCR results from patient monocytes treated with B-PMO 186.25 (3 μM and 6 μM). (D) Western blot showing 
BTK protein from B-PMO 186.25– and PMO 186.25–treated patient monocytes. Note that the anti-BTK antibody used for the monocyte lysates generates 
a strong, nonspecific band appearing just below the BTK-specific band, while the specific band is completely absent from the nontreated patient control 
cells (lane 1). Actin served as a loading control. Representative gels from 3 independent experiments are shown. The lanes separated by a black line were 
run on a different gel. The percentage of WT BTK RNA was calculated as WT RNA fraction × 100/(misspliced + WT RNA fraction). The bar graphs show the 
quantitative analysis of BTK protein as a percentage of relative intensity according to ImageJ Software. MΦ, monocytes.
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successfully used by Gatti and collaborators to treat lymphoblas-
toid cell lines derived from patients with ataxia telangiectasia (24). 
In the latter report, it was also demonstrated that fluorescently 
labeled CPP-PMOs could cross the blood-brain barrier.
While almost full restoration was obtained with B-PMO 
186.25 in patient monocytes, the correction under gymnosis con-
ditions was weaker in primary B cells as compared with that under 
electroporation. It should be noted that the restored mRNA, as 
expected, was more stable than the aberrantly spliced transcript. 
Here, it is likely that optimization of primary cell culture condi-
tions enabling long-term survival would allow uptake over several 
days, which is necessary for optimal gymnosis (53). Besides, the 
phagocytic nature of monocytes might enable easier translocation 
of CPPs in a shorter time. Since there is frequently a high capacity 
in endogenous signal transduction pathways, with only a fraction 
of proteins being, for example, phosphorylated, it is possible that 
correction of every defective BTK pre-mRNA is not needed for a 
therapeutic effect. Our findings with CPP-conjugated SCOs are 
reminiscent of the results obtained in DMD mice (57, 69, 70), in 
which B-PMOs were extraordinarily active.
This is also the first time that such modified ONs have been 
proven to work ex vivo in primary lymphoid cells, suggesting that 
the B-PMO design could become a versatile combination chem-
istry not restricted to muscle cell delivery. Of note is the fact that 
we observed a decrease in cell viability with increasing B-PMO 
concentrations in B cells, whereas monocytes were more resis-
tant. This may be due to the fragile nature of BTK-defective pri-
mary B cells compared with monocytes, which are not functionally 
affected by lack of this protein. Moreover, the fact that lympho-
blastoid cell lines treated with B-PMO SCOs showed restoration of 
the ataxia telangiectasia protein for a period of 21 days following a 
single treatment (24) demonstrates that at least certain B-lineage 
cells are highly suitable targets.
Comparing delivery by electroporation in human monocytes 
and primary B cells, we observed that lower concentrations of 
LNA-containing SCOs (1 μM) were sufficient for the correction 
in monocytes. This could be attributed to the electroporation 
method itself, which monocytes are able to resist better, whereas 
B cells get more damaged. It is possible that the electroporation 
conditions per se reduced the actual number of lymphocytes that 
are both successfully transfected and surviving, which could result 
in an underestimation of the potency of the SCO after electropo-
ration in B cells. On the other hand, there may be differences in 
the internalization of the SCOs and their subsequent intracellular 
routing. Moreover, the fact that primary human monocytes were 
readily transfectable also suggests that SCOs could represent a 
treatment option for monocyte disease.
Demonstrating not only protein restoration, but also the cor-
responding biological activity, was crucial for the splice-switch 
concept as a potential treatment modality. The fact that 2 different 
functional tests, cell viability and Y551 phosphorylation of BTK, 
yielded confirmatory results strongly suggests that the BTK pro-
tein generated is fully active.
Moreover, we also demonstrate that B-PMO 186.25 could be 
systemically administered in vivo, correcting the defect in mice 
lacking the endogenous protein but expressing the mutated human 
BTK gene. We could show that treated animals had substantial lev-
ent SCOs primarily targeting ESE sites. Using the reporter cell line 
readout, we could observe robust splice correction, as evidenced 
by restored mRNA, thus confirming the potential of this approach, 
and the best-performing SCO candidates were selected for the next 
round of experiments. Of note here, SCOs complementary to the 
3′ss of the cryptic exon showed lower efficiency compared with the 
other targeted sites. This might be due to the presence of secondary 
structures in the 3′ss, making the SCOs less efficient.
Studies in the cell line model allowed us to screen different 
LNA-modified versions of the SCOs to achieve further enhanced 
splice correction. Since LNA ONs are normally more potent, we 
investigated size-reduced versions. By decreasing the length 
from the initial 18-mers to 15-mers, the idea was that smaller 
SCOs could provide an advantage in terms of cellular uptake and 
release and hybridization specificity (49, 65). Thus, the efficiency 
of 2′OMePS SCOs was compared with the corresponding shorter 
versions. Hence, in comparison to an 18-mer 2′OMePS RNA, the 
various 15-mers composed of LNA/2′OMePS RNA had similar, or 
even higher, activity. The size factor is of relevance, since shorter 
ONs have reduced risk of accidentally targeting irrelevant RNA 
sequences if appropriately designed. The resulting enhanced 
target specificity can potentially allow lower doses to be adminis-
tered while activity in vivo is maintained (34, 49, 53). However, we 
also observed that further shortening of the SCOs, as measured in 
this in vitro model, reduced the splice-correcting activity of both 
the 186 and the 187 series. This may be secondary to the fact that 
the avidity of very short ONs simply is too low or to the fact that 
short ONs are less likely to interfere with splicing.
Next, the activity of the SCOs was assessed in the context 
of full-length, mutated human BTK pre-mRNA using either cells 
derived from the human BAC transgenic mouse or from primary 
patient monocytes carrying the intron 4 mutation. Although not 
all SCOs with different chemistries and lengths were compared 
between these 2 readouts, those tested behaved similarly. Thus, 
there was no indication of any unique secondary pre-mRNA struc-
tures imposing an altered sensitivity to the SCO-induced correc-
tion. This suggests that the identified SCOs, at least from this per-
spective, could be applied in a clinical setting.
To the best of our knowledge, this is the first time that 
exon-skipping SCOs have been successfully attempted as a treat-
ment in primary B lymphocytes, adding this lineage to the list of 
potential targets for such a therapeutic intervention (66). Of cru-
cial importance was the fact that we had the chance to obtain pri-
mary monocytes from a patient with XLA and successfully treat 
them with SCOs. This further substantiates the therapeutic poten-
tial of our SCO-based approach.
To this end, we also wanted to study naked delivery to both 
primary B cells and patient monocytes. Recently, PMO-based 
SCOs have proven to be very efficient in DMD animal models, 
especially when conjugated to a short arginine-rich peptide (i.e., 
B-PMO) belonging to the CPP group (67). Moreover, a d–amino 
acid–containing CPP-PMO was used in a thalassemia transgenic 
mouse model (68). Thus, in the context of splice switching, sev-
eral CPPs, including the B-PMO, have been used to enhance PMO 
delivery, allowing the dose to be reduced by 1 order of magnitude 
or more in vivo (33). Moreover, antisense PMOs (23) and, even 
more potently, when conjugated to the B-peptide, such SCOs were 
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to patients with XLA, vaccination against them could potentially 
yield an adequate humoral immune response by SCO-corrected B 
cells. The primary B lymphocytes responding to the vaccine would 
subsequently maturate into BTK-independent long-lived plasma 
cells exerting long-term protection. Due to the fact that the B cell 
receptor is not expressed in plasma cells, this strategy is valid for 
all primary immunodeficiencies caused by splice site mutations 
affecting this receptor complex (1).
From a therapeutic point of view, it might be feasible to 
obtain pro–B cells, carry out the treatment ex vivo, and return the 
splice-corrected cells to the patient or, alternatively, to administer 
the SCOs systemically in vivo. Ex vivo treatment has the advantage 
that any potential side effect resulting from the uptake of SCOs in 
non–B-lineage cells could be avoided. On the other hand, such a 
treatment would be more cumbersome. Thus, in vivo administra-
tion might seem more straightforward, and even if the dosage has 
not been studied in detail, it is likely that rather large doses will be 
required. If such a medicine would become available, there would 
be additional aspects to take into consideration, e.g., the cost of syn-
thesis, which is likely to be higher for in vivo delivery. Whether splice 
correction will ever become a treatment option for B cell disorders, 
or other hematopoietic diseases, remains to be seen. Here, we have 
developed a unique animal model allowing both ex vivo and in vivo 
research along this line to be conducted in a preclinical setting.
Methods
Design of SCOs. The bioinformatic algorithms of 3 different web-based 
splice servers, namely ESE Finder (74), PESX (75), and RESCUE-ESE 
(76), were used to aid in the design of the SCOs with the highest prob-
ability of success.
ONs. A list of the SCOs used is presented in Table 1. 2′OMePS RNA 
ONs were synthesized at GE Healthcare. LNA-containing ONs were syn-
thesized at the University of Southern Denmark. PMO-based ONs were 
purchased from Gene Tools and conjugation to B-PMO made at the MRC 
Laboratory of Molecular Biology. ZEN-modified ONs were made by IDT.
Reporter plasmids. The pEGFPLuc plasmid (Clontech) was used to 
construct a reporter plasmid in which the luciferase cDNA was inter-
rupted by the introduction of a mutated BTK intron 4 containing an 
A-to-T change known to result in aberrant splicing resulting in the 
inclusion of the cryptic exon (25). The introduction of this exon in the 
EGFP-luciferase fusion mRNA abolishes most of the luciferase activ-
ity. The final plasmid was designated pEGFPLuc/Btkint4mut. Cloning 
of the mutant BTK intron 4 into the EGFPLuc plasmid was done first 
by PCR amplification of a WT BTK gene intron 4, followed by site-spe-
cific mutagenesis to recreate the specific A-to-T change found in the 
patient. The cloning work was performed by Mutagenex Inc.
Cell culture and SCO transfections. The U2OS cell line stably 
expressing pEGFPLuc/Btkint4mut was generated by transfection of 
the plasmid with Fugene 6 (Roche) and selection of stable integrants 
for 3 weeks with 1 mg/ml Geneticin (Life Technologies). The stable cell 
line was designated U2OS/EGFPLucBTKint4mut. Cells were normally 
cultured in DMEM with 10% FBS and maintained at 37°C, 5% CO2 
atmosphere. For SCO transfections, cells were plated the day before at 
a density of 50,000 cells per well in a 24-well plate. Transfections were 
performed using Lipofectamine 2000 (Life Technologies) according 
to the manufacturer’s protocol, and cells were further incubated for 24 
hours. For the gymnosis/naked uptake experiments, cells were plated 
els of BTK expression both in the bone marrow and spleen, organs 
considered challenging for SCO therapy. Moreover, we could also 
demonstrate that isolated B cells, both from the bone marrow 
and spleen, expressed BTK, further proving that B-PMO reached 
the target cells and induced a therapeutic effect. At this stage, we 
have not made measurements allowing the detailed comparison 
between transcript and protein levels, for example, but rather, the 
analysis should be regarded as semiquantitative. The observation 
that upon treatment the relative amount of BTK in bone marrow 
cells seems to be lower is not unexpected, since it is likely that 
the splenocyte exposure to SCOs will be greater, due to the fact 
that more of the cardiac output reaches the spleen. One can also 
speculate that a fraction of BTK-expressing B-lineage cells in the 
bone marrow might constitute progenitor cells, adding a further 
therapeutic value. In this study, only a single multidose regimen 
was investigated, so it remains to titrate the dose and frequency of 
treatments to identify an optimal dosage. Importantly, treatment 
for just 1 week was sufficient for obtaining significant BTK restora-
tion. Thus, it is quite possible that treatment periods longer than a 
week will further increase the number of corrected cells. The opti-
mal mode of administration also remains to be tested. Since the 
treated mice were subject to combined intravenous and subcuta-
neous delivery, their respective contribution to the final treatment 
result cannot be estimated but deserves further studies.
Splenic B cells are easily accessible and constitute the preferred 
experimental source of mouse B cells. However, for obvious rea-
sons, splenocytes are not the candidate target cells for SCO therapy 
in XLA and, instead, bone marrow–resident pro–B cells are. There-
fore, we differentiated primary bone marrow progenitor cells into 
pro–B cells and subsequently transfected them with SCOs. Already 
after 48 hours, substantial amounts of BTK protein were detected 
in a high proportion of these cells, approximately to the same extent 
as that observed in mature B lymphocytes. This is an important 
piece of information, which suggests that the SCO treatment con-
cept could become applicable in a patient setting. Furthermore, it is 
known that pro–B cells from human bone marrow can be expanded 
ex vivo as described before (71). It was gratifying to observe that in 
vivo administration of B-PMOs yielded BTK restoration not only 
in the spleen, but also in the bone marrow. This bodes well for the 
concept of correcting human pro–B cells.
We also investigated the possibility of using a dual approach, 
namely to complement the SCO therapy with treatment with 
antagomirs targeting miR-185, which has been reported to nega-
tively regulate BTK expression in primary mouse cells (72). How-
ever, in preliminary experiments, the antagomir strategy was not 
sufficiently robust (unpublished observations). A single antagomir 
design was used in these experiments, and it may well be that fur-
ther optimization could improve the outcome. Thus, combining 
different ON strategies remains an attractive option with recent 
success in experimental DMD (73).
A key feature of XLA is that BTK is expressed in all B-lineage 
stages, except for the mature plasma cell (8, 9). This opens the 
possibility that even a transient correction of B-lineage cells could 
result in a long-term treatment effect. Thus, if BTK expression 
could be transiently restored at the pro–B cell stage, yielding a poly-
clonal native B cell repertoire, such cells are expected to respond 
to immunization. Since infectious agents represent a major threat 
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Material from a patient with XLA. Monocytes from a patient with 
XLA with the above-mentioned A-to-T change in intron 4 of the BTK 
gene (25) were obtained by apheresis followed by elutriation performed 
at the Centre for Apheresis and Stem Cell Processing (CASH), Karolin-
ska University Hospital. The obtained cells were ≥80% pure monocytes.
Mouse B lymphocyte preparation, culturing, and transfections. Purified 
splenic mouse B lymphocytes were obtained using an EasySep Mouse 
B Cell Enrichment Kit, which enriches cells through negative selection 
(StemCell Technologies). The purity of isolated B cells was checked by 
staining of the cell population with a PE-anti-mouse CD19 (BD Pharm-
ingen), as analyzed by flow cytometry. Purity levels were always ≥90%.
After isolation, B cells were cultured in Iscove’s Modified Dulbec-
co’s Medium (IMDM) containing 15% FBS and 50 μM β-mercaptoe-
thanol (Gibco, Life Technologies), with addition of 5 μg/ml CpG ON 
(obtained from DNA Technology A/S) for stimulation and improved 
survival of the cells in culture, as detailed in Hasan et al. (77). Lympho-
cytes were thus incubated with CpG ON for 3 to 4 hours before pro-
ceeding with the transfections.
Transfections were performed by electroporation using a Neon 
Electroporator (Invitrogen) and the 100 μl Tip Kit (Neon Transfection 
System, Life Technologies). The following settings were used: 2,100 V 
(pulse voltage); 20 ms (pulse width); 1 (pulse number). In brief, 2.4 × 106 
cells per well were resuspended in T buffer, and a volume of no more 
than 10 μl SCO per transfection per tip (i.e., maximum SCO volume 
was never more than 10% of the total resuspension volume) was 
added to the resuspended cells. Nontreated samples were treated with 
1× dPBS only. After the electrical pulse, the cells were transferred to 
a 24-well, nontissue culture-treated plate (Falcon, BD) with 400 μl 
IMDM medium containing 15% FBS and 50 μM β-mercaptoethanol. 
Cells were incubated for 4 hours, after which an additional volume of 
500 μl medium was added together with 5 μg/ml CpG ON. Cells were 
subsequently incubated for 48 hours.
For the gymnosis/naked uptake experiments, cells were plated 
at 1.5 × 106 cells per well on the day of transfection. The same CpG 
treatment was done as described above. The SCOs were given directly 
to the cells. B-PMOs were incubated at 37°C for 30 minutes and soni-
cated for a few seconds in a water bath before use. The cells were incu-
bated further for 3 to 4 days with SCOs.
XLA patient monocyte culturing and transfections. SCOs were 
transfected into the monocytes as described above with the follow-
ing settings for the Neon Electroporator: 1,800 V (pulse voltage); 
30 ms (pulse width); 1 (pulse number). After the electrical pulse, the 
cells were transferred to a 24-well, nontissue culture-treated plate 
(Falcon, BD) with 400 μl IMDM medium containing 15% FBS and 
50 μM β-mercaptoethanol. Cells were incubated for 4 hours, after 
which an additional volume of 500 μl medium was added. Cells 
were further incubated for 48 hours. Gymnosis/naked uptake exper-
iments were done as described in Mouse B lymphocyte preparation, 
culturing, and transfections.
Semiquantitative reverse transcription (RT-PCR). Cells stably trans-
fected with the reporter gene (U2OS/EGFPLucBTKint4mut) were 
washed twice with 1xPBS, and RNA was directly isolated from the 
plated cells using the RNeasy Plus Kit (Qiagen). For the mouse B cells 
and human monocytes, cells were collected and centrifuged at 500 g 
for 5 minutes and washed in 1× Dulbecco’s phosphate-buffered saline 
(dPBS; with no calcium and magnesium). RNA was isolated from the 
cell pellets using the RNeasy Plus Kit.
to reach 70% confluency at the day of transfection. The cells were incu-
bated further for 3 days with SCOs in DMEM containing 10% FBS.
Luciferase assay. For analysis of luciferase activity in the stably 
transfected U2OS cell line, cells were lysed in 300 μl RLT buffer (Pro-
mega), and 20 μl lysate was used for measuring luciferase activity with 
the Luciferase Assay Kit (Promega). Luminescence was detected using 
a FluoStar OPTIMA (BMG Labtech). Total protein was detected using 
the MicroBCA Kit (Pierce) and used for normalization of luminescence.
BAC constructs. A BAC construct carrying a mutated human BTK 
gene was obtained from TaconicArtemis GmbH. The mutated BTK 
construct was generated to contain a point mutation in intron 4 (A to 
T) at position 602 and sequence verified. This alteration is identical 
to that found in a Swedish family with XLA (25). The construct also 
contains genes and regulatory elements surrounding BTK, such as the 
genes TIMM8A, RPL36A, GLA, HNRNPH2, and part of TAF7L.
Generation and genotyping of BAC transgenic mice. Pronuclear injec-
tion of BAC DNA was performed at Karolinska Center for Transgene 
Technologies. Fertilized mouse oocytes were injected and later trans-
ferred into pseudo-pregnant females. The offspring were tested by 
DNA genotyping analysis. Ear or tail biopsies were collected from each 
mouse, and DNA was isolated (DNeasy Blood & Tissue Kit, Qiagen). 
PCR with HotStarTaq Plus DNA polymerase (Qiagen) was performed. 
Primers were designed to amplify human, but not mouse, BTK exons 
1, 11, and 19 as well as GLA and TAF7L genes. Primer sequences were 
as follows: BTK exon 1 forward, 5′-agacattggtttaggtcagg-3′; BTK exon 
1 reverse, 5′-ttttaggggtcccaagcaag-3′; BTK exon 11 forward, 5′-gagcac-
cacttcctcctaca-3′; BTK exon 11 reverse, 5′-gcacagcatcaaggagctat-3′; 
BTK exon 19 forward, 5′-cccttgaattctggattctag-3′; BTK exon 19 reverse, 
5′-agcttgggatttcctctgaga-3′; GLA forward, 5′-gaatgccaaactaacagggc-3′; 
GLA reverse, 5′-caaagtgctgggattacagg-3′; TAF7L forward, 5′-caggtcacat-
gactacacagg-3′; and TAF7L reverse, 5′-gaaagaaggtcctcggctgg-3′. 5 μM 
of each primer was used. Cycling conditions were as follows: 95°C for 
5 minutes, 30–35 cycles of 94°C for 30 seconds, 58°C (BTK) or 57°C (GLA 
and TAF7L) for 30 seconds, 72°C for 30 seconds, and a final incubation 
at 72°C for 10 minutes. RT-PCR analysis was also performed to assure 
the presence of human mutated BTK at the mRNA level in the founder 
animals. For this, RNA was isolated from purified B lymphocytes (Easy-
Sep Mouse B Cell Enrichment Kit, StemCell Technologies) using the 
RNeasy Plus Mini Kit (Qiagen). The RNA was reverse transcribed into 
cDNA using the First-Strand cDNA Synthesis Kit for RT-PCR (AMV) 
(Roche). Primer sequences were as follows: BTK intron 4 forward, 
5′-cacacaggtgaactccagaaag-3′, and BTK intron 4 reverse, 5′-agagatact-
gcccatcgatccaga-3′. Cycling conditions were as follows: 95°C for 5 min-
utes, 30 cycles of 94°C for 30 seconds, 57°C for 30 seconds, 72°C for 
30 seconds, and finally 72°C for 10 minutes. Suitable founder animals 
were selected for breeding and further experiments. Samples were run 
on 1.25% agarose gel and analyzed by Gel Doc system (Bio-Rad).
Genotyping of BAC transgenic mice bred on BTK KO background. 
Transgene-positive founder animals (C57BL/6 mice) were bred onto 
the BTK KO/C57BL/6 strain in order to create a human BAC transgenic 
mouse model expressing only the mutated human BTK gene. Here, a 
PCR was developed to distinguish among WT, heterogenic, and Btk 
KO mice. Primer sequences were as follows: Btk forward, 5′-ctgg-
gaacttcctgacagag-3′, and Btk reverse, 5′-caaaagtgcctcaaatgtgg-3′. 
Cycling conditions were as follows: 95°C for 5 minutes, 40 cycles of 
94°C for 30 seconds, 59°C for 30 seconds, 72°C for 2.5 minutes, and 
72°C for 10 minutes. These primers detect exclusively mouse Btk.
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was added to stimulate the cells. The cells were further incubated for 
24 and 48 hours. At each time point, the cells were counted using a 
Bürker chamber, and viability was determined by Trypan Blue (Invit-
rogen) exclusion. Goat F(ab′)2 anti-mouse IgM (1022-01, Southern-
Biotech) was used for both assays.
Pro–B cell culture and expansion of c-KIT+ cells. Femurs were dis-
sected from WT and BAC transgenic mice. Bone marrow was crushed 
in 5 ml 1x dPBS with 2% FCS and further subjected to magnetic-acti-
vated cell sorting column (Miltenyi Biotec) for enrichment of c-KIT+ 
cells. 10 μl immunomagnetic beads (Miltenyi Biotec) were used for the 
enrichment. After elution, the cells were resuspended in OPTIMEM 
(Life Technologies) containing 10% FCS, 50 μM β-mercaptoethanol, 
and 100X Penicillin-Streptomycin (Life Technologies). 10 ng/ml Flk-2/ 
Flt3 ligand, 10 ng/ml IL-7, and 10 ng/ml KIT ligand (all from Pepro-
tech) were added to the cell suspension. The cells were then put on top 
of a layer of OP9 cells seeded 1 day earlier, 11,000 cells per well in a 
24-well plate, and incubated. OP9 cells were maintained in OPTIMEM 
with 10% FCS and 50 μM β-mercaptoethanol. At day 5, Flk-2/Flt3 lig-
and, IL-7, and KIT ligands were added again at the same concentration. 
Until day 9, the purity and the viability of the cells were checked daily by 
flow cytometry using CD19 and propidium iodide (Life Technologies). 
At day 9, the cells were 90% pure and used for the SCO treatment.
Flow cytometry. For the staining of B lymphocytes, cells were incu-
bated in 1x dPBS with CD16/32 (clone 93, Biolegend) and subsequently 
incubated for 30 minutes at 4°C with CD19-PE (clone 1D3, BD). 
After washing twice with 1x dPBS, cells were resuspended in 1 μl/ml 
dPBS containing LIVE/DEAD Fixable Green Dead Cell Stain (Life 
Technologies) and further incubated for 30 minutes at 4°C. Then the 
cells were fixed using BD Cytofix/Cytoperm Kit according to manu-
facturer’s protocol. Subsequently, cells were stained with BTK–Alexa 
Fluor 647 (clone 53/BTK, BD) and analyzed using a FACSCalibur 
instrument (BD) at the Center for Hematology and Regenerative Med-
icine, Karolinska Institutet.
For the analysis shown in Supplemental Figure 5, bone marrow 
cells were harvested, Fc blocked (CD16/32), and stained with the fol-
lowing combination of antibodies: LY6D-FITC (clone 49-H4, BD Bio-
science), KIT-APC–Alexa Fluor 750 (2B8, eBioscience), B220-APC Cy7 
(RA3-6B2, Bioscience), CD45.1-FITC (A20, eBioscience), CD25-PE 
(PC61, Biolegend), FLT3-PE (A2F10, eBioscience), CD19-PE-CF594 
(1D3, BD), CD11c (N418, Biolegend), IgM-PE Cyanine 7 (11/41, eBio-
science), Ly6c-APC (HK14, Biolegend), CD43-APC (S11, Biolegend), 
SCA1–Pacific Blue (D7, Biolegend), IgD–Pacific Blue (11-26c.2a, Bioleg-
end), GRI-PE Cy5 (RB6-8C5, eBioscience), TER 119-PE Cy5 (TER119, 
eBioscience), CD3e- PE Cy5 (145-2c11, eBioscience), NK-1.1-PE Cy5 
(PK136, Biolegend), Mac1-PE Cy5 (X), IL7Rbio (A7R34, Biolegend), 
and streptavidin-conjugated Qdot655 (Life Technologies) to visualize 
biotinylated antibodies as well as propidium iodine. For flow cytom-
etry analysis, a LSR Fortessa instrument (BD) was used at the Center 
for Hematology and Regenerative Medicine, Karolinska Institutet. The 
analysis of the data was performed using the FlowJo Software.
BAC transgenic mice treated with B-PMO. Female age- and weight-
matched BAC transgenic mice were used for the in vivo experiments. 
200 μl B-PMO, freshly prepared as described above, or control vehi-
cle (saline) was injected in the tail vein. The mice received 30 mg/kg 
B-PMO or saline every second day for 3 injections in total. After the 
last intravenous injection, the mice were injected subcutaneously with 
another 30 mg/kg B-PMO or saline to increase the time of circulating 
RNA was reverse transcribed into cDNA using the First Strand 
cDNA Synthesis Kit for RT-PCR (AMV-Roche). PCR was performed 
with HotStarTaq Plus DNA polymerase (Qiagen). An amount of 100 ng 
of total RNA was used. Primers for determining splice correction in 
the U2OS/EGFPLucBTKint4mut cells were as follows: EGFPLuc 
Fwd-5′-ctggtgccaaccctattctccttc; EGFPLuc Rev-5′-ccagatccacaaccttc-
gcttcaa-3′. The primers used in the case of human transgene, primary 
mouse B cells and human monocytes were as follows: BTK Fwd, 
5′-cacacaggtgaactccagaaag, and BTK Rev, 5′-agagatactgcccatcgatc-
caga-3′. For the WT primary mouse B cells, another forward primer 
was used: Btk Fwd2, 5′-gagcatctttctgaagcgatccca-3′. Cycling condi-
tions were as follows: 95°C for 5 minutes, 30 cycles of 94°C for 30 sec-
onds, 57°C for 30 seconds, 72°C for 30 seconds, and finally 72°C for 
10 minutes. As an RNA quality control 18S ribosomal RNA (18s rRNA) 
was also analyzed by PCR. The primer sequences were as follows: 
18S Fwd-5′ gtaacccgttgaaccccatt; 18S Rev-5′-ccatccaatcggtagtagcg. 
Cycling conditions were as follows: 95°C for 5 minutes, 12 cycles of 
94°C for 30 seconds, 57°C for 30 seconds, 72°C for 30 seconds, and 
finally 72°C for 10 minutes. Samples were run on 1.25% agarose gel 
and analyzed by Gel Doc system (Bio-Rad). In order to ascertain the 
detection of human BTK mRNA from in vivo treated and untreated 
samples, compared with all other experiments, we decided before-
hand to use 3 times more cDNA and 5 extra amplification cycles. Gel 
densitometry analysis was done using QuantityOne Software (Bio-
Rad) in order to calculate the percentage of WT RNA.
Immunoprecipitation and immunoblotting. Immunoprecipitation 
analysis was carried using Dynabeads protein G (Life Technologies) 
according to the manufacturer’s protocol. Cell lysates were obtained, 
after washing cells in PBS twice, by incubation with lysis buffer (50 mM 
HEPES, pH 7.0, 120 mM NaCl, 10% glycerol, 1% NP-40, 0.5% sodium 
deoxycholate) supplemented with protease inhibitors (Complete Mini, 
Roche) for 30 minutes with repeated vortexing. Finally, the lysates 
were cleared by centrifugation. Proteins were separated on gradient 
4%–12% SDS Bis-Tris NuPAGE gels (Life Technologies) and trans-
ferred onto nitrocellulose membranes using the Iblot system (Invitro-
gen). The membranes were then blocked with LI-COR Blocking Buffer 
(LI-COR Biosciences GmbH) and probed with specific primary anti-
bodies. Western blots signals were scanned by using Odyssey Imager 
from LI-COR Biosciences GmbH. The following primary antibodies 
were used for detection: actin (A5441, Sigma-Aldrich), BTK (270-284, 
Sigma-Aldrich), phospho-BTK (pY551) (558129, BD), and BTK (611117, 
BD). The following secondary antibodies were used for detection: 
goat anti-mouse 800CW, goat anti-rabbit 800CW, goat anti-mouse 
680LT, or goat anti-rabbit 680 (all from LI-COR Biosciences GmbH). 
Actin was used as loading control. Quantitative analysis of BTK pro-
tein was calculated as the percentage of relative intensity by ImageJ 
software according to the manufacturer’s protocol.
Anti-IgM stimulation and functional assays. For the phosphorylation 
assay, 48 hours after electroporation, B lymphocytes were starved for 
6 hours in IMDM without serum and CpG. Cells were then pelleted and 
resuspended in 5 × 106 cells per ml in 1x dPBS. Then anti-IgM was added 
to a concentration of 20 μg/ml, and cells were incubated for exactly 
1 minute, as previously described (78). Cells were then harvested for 
immunoprecipitation and immunoblotting as described above.
For the viability test, 48 hours after electroporation, B lympho-
cytes were washed to remove the CpG and resuspended in complete 
medium with 2 × 106 cells per well. Subsequently, 20 μg/ml anti-IgM 
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B-PMO before harvesting of the organs. Two mice in each group on con-
secutive days were sacrificed 7 or 8 days after the first intravenous injec-
tion, and spleens and bone marrow were harvested for further analysis.
Statistics. Data are presented as mean ± SD. Statistical analysis was 
performed with Prism 6 (GraphPad Software). Statistical significance 
was determined using 1-way ANOVA, followed by Bonferroni’s multi-
ple-comparison test. P ≤ 0.05 was considered statistically significant.
Study approval. All animal work was performed according to 
the protocols approved by the Ethical Committee on Animal Exper-
iments, Stockholm South, Sweden. The animals were bred and 
maintained in accordance with Karolinska Institutet’s guidelines for 
animal welfare. Patients provided informed consent, and research 
involving patient materials was approved by the regional ethical com-
mittee in Stockholm (20091309-31/2).
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